Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07125872 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date changed from estimate of Aug 19, 2025 to Nov 11, 2025 · Secondary endpoints: details revised at 1 of 1 entry · 2 morev2 Show 5 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Aug 19, 2025 to Nov 11, 2025
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study title shortened, about 14 words
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Trial Details
NCT Number NCT07125872
Lead Sponsor ImmunityBio, Inc.
Conditions Relapsed B-Cell Non Hodgkin Lymphoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov